Clinical Trials
9
Active:0
Completed:6
Trial Phases
1 Phases
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (100.0%)Using CTA Measures to Define Cardiac Risk In NFL Alumni
Recruiting
- Conditions
- Coronary Artery Disease (CAD)Heart DiseaseCoronary Atherosclerosis
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- HeartFlow, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06831409
- Locations
- 🇺🇸
Stanford, Stanford, California, United States
🇺🇸Boone Heart Institute, Greenwood Village, Colorado, United States
AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- HeartFlow, Inc.
- Target Recruit Count
- 10000
- Registration Number
- NCT06376851
- Locations
- 🇺🇸
Moses Cone Memorial Hospital, Greensboro, North Carolina, United States
Assessing Diagnostic Value of Non-invasive FFR-CT (Fractional Flow Reserve - Computed Tomography) in Coronary Care in the Emergency Department
Terminated
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- HeartFlow, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05325112
- Locations
- 🇺🇸
UMass Memorial Hospital, Worcester, Massachusetts, United States
🇺🇸University Hospital Clevelan, Cleveland, Ohio, United States
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
Completed
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- HeartFlow, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT05138289
- Locations
- 🇺🇸
HeartFlow Investigative Site, Lincoln, Nebraska, United States
The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization
Not Applicable
Completed
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- HeartFlow, Inc.
- Target Recruit Count
- 2103
- Registration Number
- NCT03702244
- Locations
- 🇺🇸
Participating site, Lake Charles, Louisiana, United States
- Prev
- 1
- 2
- Next
News
No news found